NCT03267147View on ClinicalTrials.gov

PREVALENCE OF Anti-CCP POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS

CompletedOBSERVATIONAL
Enrollment

986

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

December 16, 2021

Study Completion Date

February 15, 2022

Conditions
Rheumatoid Arthritis
Interventions
OTHER

no intervention is given

no intervention is given

Trial Locations (1)

60596

CIRI, Frankfurt am Main

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Goethe University

OTHER

lead

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

OTHER

NCT03267147 - PREVALENCE OF Anti-CCP POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS | Biotech Hunter | Biotech Hunter